Risk Assessment Tools in Pulmonary Arterial Hypertension. Prognosis for Prospective Trials?

Patients with PAH still experience disease progression and increased rates of hospitalizations; moreover, hospitalization is a harbinger of disease progression and early mortality (2, 3). [...]along with improving PAH treatment options, developing appropriate and accurate risk prediction is essentia...

Full description

Saved in:
Bibliographic Details
Published inAmerican journal of respiratory and critical care medicine Vol. 197; no. 7; pp. 843 - 845
Main Authors Farber, Harrison W, Benza, Raymond L
Format Journal Article
LanguageEnglish
Published United States American Thoracic Society 01.04.2018
Subjects
Cardiology
Clinical trials
Medical diagnosis
Medical prognosis
Mortality
Patients
Pulmonary hypertension
Risk assessment
Online AccessGet full text

Cover

More Information
Summary:Patients with PAH still experience disease progression and increased rates of hospitalizations; moreover, hospitalization is a harbinger of disease progression and early mortality (2, 3). [...]along with improving PAH treatment options, developing appropriate and accurate risk prediction is essential to make rational and individualized treatment decisions and, as such, improve outcomes in PAH. [...]most clinicians feel they are better decision-makers than they actually demonstrate in clinical practice. For these reasons, scoring systems are valuable additions to our clinical gestalt. [...]most surrogates we have used to define clinical status are not sufficiently accurate singly, nor has any grouping been studied in a robust, prospective manner. In all likelihood, this will mean using parameters from several different risk calculators to satisfy the requirements noted here. [...]we do not know whether certain parameters might differ depending on ethnicity or geographical region.
Bibliography:SourceType-Other Sources-1
content type line 63
ObjectType-Editorial-2
ObjectType-Commentary-1
ISSN:1073-449X
1535-4970
DOI:10.1164/rccm.201801-0042ed